Discovery of proqodine A derivatives with antitumor activity targeting NAD(P)H: quinone oxidoreductase 1 and nicotinamide phosphoribosyltransferase

Abstract

NAD(P)H: quinone oxidoreductase 1 (NQO1) is a flavin protease highly expressed in various cancer cells. NQO1 catalyzes a futile redox cycle in substrates, leading to substantial reactive oxygen species (ROS) production. This ROS generation results in extensive DNA damage and elevated poly (ADP-ribose) polymerase 1 (PARP1)-mediated consumption of nicotinamide adenine dinucleotide (NAD⁺), ultimately causing cell death. Nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD⁺ salvage synthesis pathway, emerges as a critical target in cancer therapy. The concurrent inhibition of NQO1 and NAMPT triggers hyperactivation of PARP1 and intensive NAD⁺ depletion. In this study, we designed, synthesized, and assessed a novel series of proqodine A derivatives targeting both NQO1 and NAMPT. Among these, compound T8 demonstrated potent antitumor properties. Specifically, T8 selectively inhibited the proliferation of MCF-7 cells and induced apoptosis through mechanisms dependent on both NQO1 and NAMPT. This discovery offers a promising new molecular entity for advancing anticancer research.

Keywords

NQO1 / ROS / NAMPT / NAD⁺ / T8

References

[1] Hanahan D, Weinberg RA. The hallmarks of cancer[J]. Cell, 2000, 100(1): 57-70.

[2] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674.

[3] Yaku K, Okabe K, Hikosaka K, et al. NAD metabolism in cancer therapeutics[J]. Front Oncol, 2018, 8: 622.

[4] Kennedy BE, Sharif T, Martell E, et al. NAD⁺salvage pathway in cancer metabolism and therapy[J]. Pharmacol Res, 2016, 114: 274-283.

[5] Belenky P, Bogan KL, Brenner C. NAD⁺metabolism in health and disease[J]. Trends Biochem Sci, 2007, 32(1): 12-19.

[6] Luengo A, Gui DY, Vander HMG. Targeting metabolism for cancer therapy[J]. Cell Chem Biol, 2017, 24(9): 1161-1180.

[7] Pink JJ, Planchon SM, Tagliarino C, et al. NAD(P)H: quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity[J]. J Biol Chem, 2000, 275(8): 5416-5424.

[8] Zhu H, Li YB. NAD(P)H: quinone oxidoreductase 1 and its potential protective role in cardiovascular diseases and related conditions[J]. Cardiovasc Toxicol, 2012, 12(1): 39-45.

[9] Siegel D, Yan C, Ross D. NAD(P)H: quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones[J]. Biochem Pharmacol, 2012, 83(8): 1033-1040.

[10] Winski SL, Koutalos Y, Bentley DL, et al. Subcellular localization of NAD(P)H: quinone oxidoreductase 1 in human cancer cells[J]. Cancer Res, 2002, 62(5): 1420-1424.

[11] Nakamura M, Hayashi T. One- and two-electron reduction of quinones by rat liver subcellular fractions[J]. J Biochem, 1994, 115(6): 1141-1147.

[12] Park EJ, Min KJ, Lee TJ, et al. β-Lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells[J]. Cell Death Dis, 2014, 5(5): e1230.

[13] Ross D, Kepa JK, Winski SL, et al. NAD(P)H: quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms[J]. Chem Biol Interact, 2000, 129(1-2): 77-97.

[14] Chakrabarti G, Silvers MA, Ilcheva M, et al. Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone[J]. Sci Rep, 2015, 5: 17066.

[15] Moore Z, Chakrabarti G, Luo X, et al. NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone[J]. Cell Death Dis, 2015, 6(1): e1599.

[16] Wang GY, Zhang L, Geng YD, et al. β-Elemene induces apoptosis and autophagy in colorectal cancer cells through regulating the ROS/AMPK/mTOR pathway[J]. Chin J Nat Med, 2022, 20(1): 9-21.

[17] Dong Y, Bey EA, Li LS, et al. Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation [J]. Cancer Res, 2010, 70( 20): 8088-8096.

[18] Bey EA, Bentle MS, Reinicke KE, et al. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone[J]. Proc Natl Acad Sci USA, 2007, 104(28): 11832-11837.

[19] Cresteil T, Jaiswal AK. High levels of expression of the NAD(P)H: quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin[J]. Biochem Pharmacol, 1991, 42(5): 1021-1027.

[20] Siegel D, Franklin WA, Ross D. Immunohistochemical detection of NAD(P)H: quinone oxidoreductase in human lung and lung tumors[J]. Clin Cancer Res, 1998, 4(9): 2065-2070.

[21] Beall HD, Murphy AM, Siegel D, et al. Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines[J]. Mol Pharmacol, 1995, 48(3): 499-504.

[22] Huang X, Dong Y, Bey EA, et al. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis[J]. Cancer Res, 2012, 72(12): 3038-3047.

[23] Nakae K, Adachi H, Sawa R, et al. NAD(P)H quinone oxidoreductase 1 (NQO1)-bioactivated pronqodine A regulates prostaglandin release from human synovial sarcoma cells[J]. J Nat Prod, 2013, 76(4): 510-515.

[24] Mori V, Amici A, Mazzola F, et al. Metabolic profiling of alternative NAD biosynthetic routes in mouse tissues[J]. PLoS One, 2014, 9(11): e113939.

[25] Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells[J]. J Biol Chem, 2004, 279(49): 50754-50763.

[26] Liu HY, Li QR, Cheng XF, et al. NAMPT inhibition synergizes with NQO1-targeting agents in inducing apoptotic cell death in non-small cell lung cancer cells[J]. Chin J Nat Med, 2016, 14(8): 582-589.

[27] Zhang KJ, Wang KZ, Zhang XY, et al. Discovery of small molecules simultaneously targeting NAD(P)H: quinone oxidoreductase 1 and nicotinamide phosphoribosyltransferase: treatment of drug-resistant non-small-cell lung cancer[J]. J Med Chem, 2022, 65(11): 7746-7769.

[28] Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis[J]. Cancer Res, 2003, 63(21): 7436-7442.

[29] Holen K, Saltz LB, Hollywood E, et al. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor[J]. Invest New Drugs, 2008, 26(1): 45-51.

[30] Galli U, Ercolano E, Carraro L, et al. Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage[J]. Chem Med Chem, 2008, 3(5): 771-779.

[31] Colombano G, Travelli C, Galli U, et al. A novel potent nicotinamide phosphoribosyltransferase inhibitor synthesized via click chemistry[J]. J Med Chem, 2010, 53(2): 616-623.

[32] Olesen UH, Christensen MK, Björkling F, et al. Anticancer agent CHS-828 inhibits cellular synthesis of NAD[J]. Biochem Biophys Res Commun, 2008, 367(4): 799-804.

[33] Watson M, Roulston A, Bélec L, et al. The small molecule GMX1778 is a potent inhibitor of NAD⁺biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors[J]. Mol Cell Biol, 2009, 29(21): 5872-5888.

[34] Ravaud A, Cerny T, Terret C, et al. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study[J]. Eur J Cancer, 2005, 41(5): 702-707.

[35] von Heideman A, Berglund A, Larsson R, et al. Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data[J]. Cancer Chemother Pharmacol, 2010, 65(6): 1165-1172.

[36] Blunt CE, Torcuk C, Liu Y, et al. Synthesis and intracellular redox cycling of natural quinones and their analogues and identification of indoleamine-2, 3-dioxygenase (IDO) as potential target for anticancer activity[J]. Angew Chem Int Ed, 2015, 54(30): 8740-8745.

[37] Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening[J]. Nat Protoc, 2006, 1(3): 1112-1116.

[38] Liu P, Li H, Cepeda J, et al. Regulation of inflammatory cytokine expression in pulmonary epithelial cells by pre-B-cell colony-enhancing factor via a nonenzymatic and AP-1-dependent mechanism[J]. J Biol Chem, 2009, 284(40): 27344-27351.

[39] Skelly JV, Sanderson MR, Suter DA, et al. Crystal structure of human DT-diaphorase: a model for interaction with the cytotoxic prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)[J]. J Med Chem, 1999, 42(21): 4325-4330.

Funding

National Key Research and Development Programme of China(YFA1303800)

Fundamental Research Funds for the Central Universities(2632023TD10)

National Natural Science Foundation of China(81930109)